Should older adults with AML receive post-remission therapy?
1Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, D-2053, Boston, MA 02215, USA.
Best Practice & Research. Clinical Haematology
|November 23, 2015
Summary
Intensive post-remission therapy is often unsuitable for older adults with acute myeloid leukemia (AML) due to tolerance issues and disease resistance. Treatment goals for these patients may focus on life-prolonging or palliative care rather than cure.
Area of Science:
- Hematology
- Geriatric Medicine
- Oncology
Background:
- Post-remission therapy for acute myeloid leukemia (AML) in older adults has largely followed regimens for younger patients.
- However, older adults exhibit poorer therapy tolerance and increased disease resistance, questioning the suitability of these intensive approaches.
Purpose of the Study:
- To review current treatment strategies for older adults diagnosed with AML.
- To provide guidance on selecting appropriate therapies considering the unique challenges in this demographic.
Main Methods:
- Literature review of studies focusing on acute myeloid leukemia treatment in elderly populations.
- Analysis of treatment outcomes and tolerance in patients aged 55-65 years and older.
Main Results:
- Intensive post-remission therapy is not appropriate for most older AML patients.
- The role of intensive induction therapy in this age group remains uncertain.
- Treatment objectives for older AML patients often shift towards life-prolongation or palliation.
Conclusions:
- Standard intensive AML therapies require adaptation for older adults.
- Tailoring treatment based on individual tolerance and revised goals is crucial for optimizing care in elderly AML patients.
Related Concept Videos
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
316
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
316
02:56Treatment Resistent Cancers
1.5K
1.5K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
317
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
317
01:15Drug Dosing: Geriatric Patients
347
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
347
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:22Bone Marrow Sampling and Transplants
2.4K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.4K